insights_auto
Outlook: 82.3% bullish·2.9% bearish
Go to analysischevron_right
BIIB34:BVMF
Biogen Inc BDR
R$193.80
0.00%
(0.00) 1D
Oct 14, 12:51:04 PM GMT-3 · BRL
search
All symbols
No data
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BIIB34...
Mkt. cap
36.81B
Avg. vol.
8.00
Volume
0.00
52-wk high
R$193.80
52-wk low
R$132.99
Shares outstanding
147.82M
No. of employees
8K
Mkt. cap
36.81B
Avg. vol.
8.00
Volume
0.00
52-wk high
R$193.80
52-wk low
R$132.99
Shares outstanding
147.82M
No. of employees
8K
News stories
From web sources and news partners
Investing.com
·
16 hours ago
Guggenheim raises Biogen stock price target to $300 on growth portfolio strength
Reuters
·
1 day ago
Biogen shares tank on scrapping Alzheimer trials
Profile
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. The company's primary products are dimethyl fumarate, diroximel fumarate, interferon beta-1a, peginterferon beta-1a, and natalizumab, all for the treatment of multiple sclerosis; nusinersen for the treatment of spinal muscular atrophy; omaveloxolone for the treatment of Friedreich's ataxia; tofersen for the treatment of ALS; and dimethyl fumarate for the treatment of severe plaque psoriasis. The company also produces 5 biosimilars and has collaborations with Genentech for several drugs.
The company is ranked 424th on the Fortune 500 and 845th on the Forbes Global 2000. Wikipedia
About Biogen Inc BDR
CEOChris Viehbacher
Employees7.5K
Founded1978
HeadquartersCambridge, Massachusetts, United States
SectorBiotechnology
Websitebiogen.com
Previous reports
Loading Previous Earnings...
Income statement
Revenue
Net income
- Quarterly
- Annual
All values in USD | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
Revenue | 2.28B | 2.48B | 2.74B | 2.80B |
Cost of goods sold | 443.40M | 1.09B | 1.10B | 1.13B |
Cost of revenue | 443.40M | 1.09B | 1.10B | 1.13B |
Research and development expenses | 477.10M | - | - | - |
Total research and development expenses | - | - | - | - |
Selling, general, and admin expenses | 685.20M | 607.30M | 709.70M | 752.00M |
Operating expense | 1.36B | 818.00M | 946.70M | 1.00B |
Total operating expenses | 1.81B | 1.91B | 2.05B | 2.13B |
Operating income | 471.60M | 567.40M | 685.60M | 676.30M |
Other non operating income | 17.40M | -1.10M | 3.00M | 11.20M |
EBT including unusual items | -56.00M | 377.70M | 132.40M | -9.00M |
EBT excluding unusual items | 447.00M | 530.10M | 625.10M | 603.00M |
Income tax expense | -7.10M | 58.20M | 34.90M | 11.60M |
Effective tax rate | 12.68% | 15.41% | 26.36% | -128.89% |
Other operating expenses | 69.90M | 74.20M | 68.80M | 77.80M |
Net income | -48.90M | 319.50M | 97.50M | -20.60M |
Net profit margin | -2.15% | 12.89% | 3.56% | -0.73% |
Earnings per share | 1.99 | 3.57 | 3.60 | 2.62 |
Interest and investment income | 37.20M | 37.90M | 25.30M | 9.30M |
Interest expense | -67.50M | -67.60M | -82.30M | -87.50M |
Net interest expenses | -30.30M | -29.70M | -57.00M | -78.20M |
Depreciation and amortization charges | - | - | - | - |
EBITDA | 671.80M | 771.80M | 921.70M | 917.40M |
Gain or loss from assets sale | - | - | - | - |
Upcoming events